文献速递肺栓塞与肺血管病

无诱因肺栓塞后复发静脉血栓栓塞的危险因素:PADIS-PE随机试验

Risk factors for recurrent venous thromboembolism after unprovoked pulmonary embolism: the PADIS-PE randomised trial.
PubMed 文献 · Eur Respir J · 2018-01-04

基于双盲随机PADIS-PE试验371例首次无诱因肺栓塞患者,初始抗凝6个月后随机接受额外18个月华法林或安慰剂,停药后随访2年。中位随访41个月,67例复发VTE(6.8/100人年)。多因素分析显示年龄、6个月时肺血管阻塞指数≥5%及抗磷脂抗体为复发独立预测因素。

要点

  • 年龄50-65岁及>65岁者复发VTE风险显著升高。
  • 抗凝6个月时PVOI≥5%与抗磷脂抗体阳性为独立预测因素。
  • 若6个月PVOI不可得,诊断时PVOI≥40%亦与复发风险约2倍升高相关。

核心结论

  • 首次无诱因肺栓塞后,年龄、肺栓塞诊断时或抗凝6个月后PVOI及抗磷脂抗体为复发VTE独立预测因素。

研究设计与样本

  • 基于双盲随机PADIS-PE试验,纳入371例首次无诱因肺栓塞患者,初始治疗6个月后随机接受额外18个月华法林或安慰剂,停药后随访2年。
  • 所有患者入选时(抗凝6个月)均行通气/灌注肺扫描。

主要发现

  • 中位随访41个月,371例中67例复发VTE,发生率6.8/100人年。
  • 多因素分析中,年龄50-65岁复发HR 3.65(95%CI 1.33-9.99),年龄>65岁HR 4.70(95%CI 1.78-12.40)。
  • 抗凝6个月时PVOI≥5%者复发HR 2.06(95%CI 1.14-3.72),抗磷脂抗体阳性者HR 2.38(95%CI 1.15-4.89)。
  • 肺栓塞诊断时PVOI≥40%(见于40%患者)亦与复发风险约2倍增加相关。

临床怎么用

  • 对无诱因肺栓塞患者,可结合年龄、诊断时或抗凝6个月后PVOI及抗磷脂抗体评估复发风险。
  • 抗凝6个月时PVOI≥5%或抗磷脂抗体阳性提示复发风险升高,可作为延长抗凝决策参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We aimed to identify risk factors for recurrent venous thromboembolism (VTE) after unprovoked pulmonary embolism.Analyses were based on the double-blind randomised PADIS-PE trial, which included 371 patients with a first unprovoked pulmonary embolism initially treated during 6 months who were randomised to receive an additional 18 months of warfarin or placebo and followed up for 2 years after study treatment discontinuation. All patients had ventilation/perfusion lung scan at inclusion (i.e. at 6 months of anticoagulation).During a median follow-up of 41 months, recurrent VTE occurred in 67 out of 371 patients (6.8 events per 100 person-years). In main multivariate analysis, the hazard ratio for recurrence was 3.65 (95% CI 1.33-9.99) for age 50-65 years, 4.70 (95% CI 1.78-12.40) for age >65 years, 2.06 (95% CI 1.14-3.72) for patients with pulmonary vascular obstruction index (PVOI) ≥5% at 6 months and 2.38 (95% CI 1.15-4.89) for patients with antiphospholipid antibodies. When considering that PVOI at 6 months would not be available in practice, PVOI ≥40% at pulmonary embolism diagnosis (present in 40% of patients) was also associated with a 2-fold increased risk of recurrence.After a first unprovoked pulmonary embolism, age, PVOI at pulmonary embolism diagnosis or after 6 months of anticoagulation and antiphospholipid antibodies were found to be independent predictors for recurrence.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Tromeur C, Sanchez O, Presles E, et al. Risk factors for recurrent venous thromboembolism after unprovoked pulmonary embolism: the PADIS-PE randomised trial. Eur Respir J. 2018. PMID: 29301920. doi:10.1183/13993003.01202-2017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。